Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
259
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

321
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
321
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

439
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
439
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Tumour Mutational Burden and Its Relationship with Clinical Outcomes in Locally Advanced and Recurrent/Metastatic Adenoid Cystic Carcinoma with and Without NOTCH Pathway Activation.

Cancers·2026
Same author

Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center.

Endocrine·2026
Same author

Defining physician acceptance of radiosensitivity testing for guiding therapeutic interventions in head and neck cancer: A Delphi consensus study.

Clinical and translational radiation oncology·2026
Same author

Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity.

Science advances·2026
Same author

Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial.

European journal of cancer (Oxford, England : 1990)·2026

関連する実験動画

Updated: Sep 9, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K

トリリンX: ランダム化,第3相研究

Jean Bourhis1, Lisa F Licitra2, Barbara Burtness3

  • 1Radiation Oncology Department, Bâtiment Hospitalier, CHUV, Lausanne, Switzerland.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
|September 3, 2025
PubMed
まとめ

化学放射線療法 (CRT) にキセビナパントを添加すると,未切除の局所進行性状細胞癌 (LA SCCHN) の患者では,無事生存率 (EFS) が改善しなかった. この組み合わせは,プラセボとCRTと比較して,より悪い安全性プロファイルを示しました.

さらに関連する動画

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.6K
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

9.9K

関連する実験動画

Last Updated: Sep 9, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.6K
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

9.9K

科学分野:

  • 腫瘍学
  • 臨床試験
  • 頭 頸部 がん の 治療

背景:

  • 局所進行性状細胞癌 (LA SCCHN) は難しい診断です.
  • 標準的な治療は化学放射線療法 (CRT) ですが,改善は可能です.
  • アポトーシスタンパク質の阻害剤 (IAP) は潜在的な治療標的である.

研究 の 目的:

  • 切開されていないLASCCHN患者のCRTにIAP阻害剤であるxevinapantを加える効果と安全性を評価する.
  • この研究は,セビナパントがプラセボと比較してイベントフリー生存率 (EFS) を改善するかどうかを決定することを目的とした.

主な方法:

  • ランダム化され,ダブルブラインドで,第3相試験 (TrilynX) が実施された.
  • 患者は口服用ゼビナパントまたはプラセボを6サイクル,CRT (シスプラチンと強度調節放射線療法) を3サイクル併用した.
  • 主要エンドポイントはEFSで,次要エンドポイントは全生存率 (OS) と安全性でした.

主要な成果:

  • クセビナパントのEFSの中央値はプラセボ (33.1ヶ月) よりも短かった (HR,1. 33;P = . 9919).
  • クセビナパントのグループでは,全生存率が低下した (HR,1. 39).
  • 治療によるグレード3以上の有害事象は,貧血と中性不全のより高い割合を含むプラセボ (80. 3%) と比較してXevinapantでより頻繁に発生しました.

結論:

  • 切開されていないLA SCCHNの患者では,XevinapantとCRTはEFSを改善しませんでした.
  • クセビナパントの追加は,プラセボと比較して不利な安全性プロファイルを示した.
  • 現時点のデータによると,この患者群ではクセビナパントは有益ではない.